Already registered? Need to register? Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

TAUSSIG

PlayTAUSSIG: Evolocumab shows benefit in children with homozygous familial hypercholesterolaemia

TAUSSIG: Evolocumab shows benefit in children with homozygous familial hypercholesterolaemia

ESC Congress 2017: First data in children with homozygous familial hypercholesterolaemia (FH, inherited high cholesterol) aged from 12 years show that evolocumab is an effective option, added to statin and ezetimibe with or without lipoprotein apheresis (1). Homozygous FH is a rare genetic disorder characterised…

read more »
TAUSSIG: What does it mean for the homozygous FH patient?

TAUSSIG: What does it mean for the homozygous FH patient?

Data from TAUSSIG (Trial Assessing Long-Term Use of PCSK9 Inhibition in Subjects with Genetic LDL Disorders), the largest and longest study of lipid lowering therapy in patients with homozygous FH, indicate a complementary role for evolocumab with lipoprotein apheresis. PCSK9 Forum Editor Dr Peter Lansberg…

read more »
PlayTAUSSIG: Does adding evolocumab reduce cardiovascular events in homozygous FH?

TAUSSIG: Does adding evolocumab reduce cardiovascular events in homozygous FH?

84th European Atherosclerosis Society Congress, 29 May- 1 June, Innsbruck, Austria Patients with homozygous familial hypercholesterolaemia (FH, inherited high cholesterol) are at extremely high risk of premature cardiovascular events due to the burden of elevated LDL cholesterol. Indeed, cardiovascular death at an early age is…

read more »
PlayISA 2015: Evolocumab in TAUSSIG homozygous FH cohort

ISA 2015: Evolocumab in TAUSSIG homozygous FH cohort

News from one of the largest cohort of patients with homozygous familial hypercholesterolaemia (FH, inherited high cholesterol) in the TAUSSIG (Trial Assessing Long-Term Use of PCSK9 Inhibition in Subjects With Genetic LDL Disorders) study strengthens the data for evolocumab.1 In 100 patients with homozygous FH,…

read more »
AHA Scientific Sessions – TAUSSIG analysis: Homozygous FH patients on lipid apheresis

AHA Scientific Sessions – TAUSSIG analysis: Homozygous FH patients on lipid apheresis

Treatment with PCSK9 monoclonal antibody therapy results in further LDL-C lowering in patients with homozygous familial hypercholesterolaemia (FH ) receiving lipid apheresis, provided that they have at least one LDL receptor-defective mutation, according to data from the Trial Assessing Long-Term Use of PCSK9 Inhibition in…

read more »